|
|
|
| Effect of preoperative concurrent chemoradiotherapy combined with surgery in the treatment of esophageal cancer |
| Balshaguri·Zabihuula Mukhdes·Ilias |
| Department of Thoracic and Abdominal Radiotherapy, Tumor Hospital Affiliated to Xinjiang Medical University, Xinjiang Uygur Autonomous Region, Urumqi 830011, China |
|
|
|
Abstract Objective To investigate the clinical effect of preoperative concurrent chemoradiotherapy combined with surgery in the treatment of esophageal cancer. Methods From January 2016 to December 2018, 51 patients with esophageal cancer admitted to the Tumor Hospital Affiliated to Xinjiang Medical University were selected and divided into the observation group (n = 27) and the control group (n = 24) according to the random number table method. The observation group received Docetaxel+Cisplatin chemotherapy before surgery, and received three-dimensional conformal radiotherapy simultaneously. Surgery was performed 2 weeks after chemotherapy. The control group received surgical treatment directly. The complete resection, perioperative complications, 1-year, 2-year and 3-year survival rates of patients were compared between the two groups. The occurrence of short-term curative effect and toxic side effect in the observation group was recorded. Results After eliminating the lost follow-up cases, 26 cases remained in the observation group and 22 cases in the control group. The objective remission rate (ORR) and disease control rate (DCR) were 92.31% and 100.00% respectively in the observation group after preoperative concurrent chemoradiotherapy. In the observation group, acute toxic side effects of grade Ⅲ or above included neutropenia in 2 cases, thrombocytopenia in 1 case, nausea/vomiting in 4 cases, alopecia in 5 cases and radiation dermatitis in 1 case. The complete resection rate and 1-year, 2-year and 3-year survival rate in the observation group were significantly higher than those in the control group, with statistically significant differences (P ＜ 0.05). There was no significant difference in the incidence of perioperative complications between the two groups (P ＞ 0.05). Conclusion Preoperative concurrent chemoradiotherapy combined with surgical treatment can improve the survival rate and complete resection rate of patients with in vitro squamous cell carcinoma.
|
|
|
|
|
|
[1] Zeng H，Zheng R，Zhang S，et al. Esophageal cancer statistics in China，2011：Estimates based on 177 cancer registries [J]. Thoracic Cancer，2016，7（2）：232-237.
[2] 张思维，郑荣寿，左婷婷，等.中国食管癌死亡状况和生存分析[J].中华肿瘤杂志，2016，38（9）：709-715.
[3] Franco P，Arcadipane F，Ragona R，et al. Locally Advanced （T3-T4 or N+） Anal Cancer Treated with Simultaneous Integrated Boost Radiotherapy and Concurrent Chemotherapy [J]. Anticancer Research，2016，36（4）：2027-2032.
[4] 王修身，张羲茜，刘晓，等.食管癌同步放化疗的疗效及预后因素分析[J].中华放射肿瘤学杂志，2017，26（4）：400-404.
[5] 杨学宁，吴一龙.实体瘤治疗疗效评价标准-RECIST[J]. 循证医学，2004，4（2）：85-90，111．
[6] Kaba H，Fukuda H，Yamamoto S，et al. Reliability at the National Cancer Institute-Common Toxicity Criteria version 2.0 [J]. Gan To Kagaku Ryoho，2004，31（8）：1187-1192.
[7] 洪澜，谭程，薛杨，等.术前放化疗联合微创食管切除术治疗晚期食管鳞癌疗效观察[J].山东医药，2016，56（6）：50-51.
[8] 张月峰，景绍武，王军，等.食管癌根治性术后辅助放化疗临床疗效Meta分析[J].中华肿瘤防治杂志，2015，22（9）：713-718.
[9] 王会恩，薛文飞，赵庆涛，等.管状胃代食管在食管下段癌根治术消化道重建中的临床价值[J].疑难病杂志，2019， 18（11）：1118-1121，1127.
[10] 解立俊，唐俊霞.瑞芬太尼联合不同药物对食管癌根治术患者炎症反应及肺功能的影响[J].中国现代医生，2018，56（4）：123-125，129.
[11] 王利利，王坚，汪建林，等.老年食管癌患者单纯放疗和同步放化疗的临床研究[J].中华放射医学与防护杂志，2018，38（12）：907-911.
[12] 郑洁，吴星娆，叶岚，等.ⅡB-ⅢB期宫颈鳞癌同步放化疗与新辅助化疗后同步放化疗疗效比较[J].中华放射肿瘤学杂志，2018，27（1）：58-62.
[13] 张文璎，薛月珍，陶敏芳.拓扑替康、顺铂和泰素对宫颈癌HeLa细胞的抑制及放射增敏作用[J].上海交通大学学报：医学版，2010，30（2）：158-161.
[14] Viswanathan AN，Lee LJ，Eswara JR，et al. Complications of pelvic radiation in patients treated for gynecologic malignancies [J]. Cancer，2014，120（24）：3870-3883.
[15] 高立伟，李宁宁，王继英，等.局部晚期非小细胞肺癌同步放化疗过程中肿瘤退缩的相关因素分析[J].中国医刊，2018，53（2）：224-227.
[16] 王道军，赵山虎，夏平，等.肿瘤坏死因子-α诱导蛋白8样分子1在食管癌中的表达及其作用机制研究[J].疑难病杂志，2019，18（12）：1258-1262.
[17] 喻春钊，陶德定，冯永东，等.联合放/化疗对细胞周期特异性凋亡的影响[J].肿瘤，2005，25（1）：10-14.
[18] 郭潇，赵钦，张玉宇，等.术前同步放化疗对ⅡB～ⅢA期宫颈癌患者手术切除率的影响[J].中国老年学，2012， 32（7）：1383-1384.
[19] 林佳，庄梅生，王继宇，等.Ⅱb～Ⅲ期食管癌术后放疗与序贯放化疗的临床效果观察[J].中国医药科学，2018，8（3）：180-183.
[20] 李学健，贾慧，宋平平，等.术前同步放化疗联合手术治疗局部晚期食管癌的疗效评价[J].中国肿瘤外科杂志，2014，6（2）：77-79，92.
[21] 王鑫，祝淑钗.食管癌综合治疗研究进展[J].中华放射肿瘤学杂志，2006，15（1）：65-68.
[22] 茹仙古丽·艾尔西丁，木拉提·哈米提，严传波，等.新疆哈萨克族食管癌图像特征提取及分型方法的探讨[J].北京生物医学工程，2019，38（3）：257-262.
[23] Rohatgi PR，Swisher SG，Correa AM，et al. Histologic subtypes as determinants of outcome in esophageal carcinoma patients with pathologic complete response after preoperative chemoradiotherapy [J]. Cancer，2006，106（3）：552-558.
[24] 蒋亦燕，吴式琇，张萍，等.常规剂量紫杉醇联合顺铂术前同步放化疗治疗胸段食管癌的临床研究[J].中华医学杂志，2008，88（31）：2171-2174. |
|
|
|
